Alogliptin Benzoate Dimer Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

1268836-55-0Alogliptin Benzoate Dimer Impurity

● In Stock

Catalogue No.:VL5900040
CAS No.:1268836-55-0
Mol. Formula:C31H30N8O4
Mol. Weight:578.64 g/mol

Additional information on CAS 1268836-55-0

Parent drug

Alogliptin

IUPAC Name

6-Despiperidinyl-6-(alogliptin-Namino-yl) Alogliptin

Pharmacopoeial Synonyms

N/A

Other Synonyms

2-[[6-[[(3R)-1-[3-[(2-Cyanophenyl)methyl]-1-methyl-2,6-dioxopyrimidin-4-yl]piperidin-3-yl]amino]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile

Smiles

N#CC1=CC=CC=C1CN(C(N2C)=O)C(N3C[C@H](NC(N(CC4=CC=CC=C4C#N)C5=O)=CC(N5C)=O)CCC3)=CC2=O

InChI

InChI=1S/C31H30N8O4/c1-35-28(40)14-26(38(30(35)42)18-23-10-5-3-8-21(23)16-32)34-25-12-7-13-37(20-25)27-15-29(41)36(2)31(43)39(27)19-24-11-6-4-9-22(24)17-33/h3-6,8-11,14-15,25,34H,7,12-13,18-20H2,1-2H3/t25-/m1/s1

Description

Alogliptin Benzoate Dimer Impurity, also known as 2-[[6-[[(3R)-1-[3-[(2-Cyanophenyl)methyl]-1-methyl-2,6-dioxopyrimidin-4-yl]piperidin-3-yl]amino]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile is a highly characterized reference material. It fully complies with stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Alogliptin. Moreover, it comes with a detailed Structure Elucidation Report (SER), ensuring its accuracy and reliability for a wide range of analytical applications. » Alogliptin Benzoate Dimer Impurity (CAS No: 1268836-55-0) or 6-Despiperidinyl-6-(alogliptin-Namino-yl) Alogliptin is an impurity of Alogliptin that is used in the treatment of type 2 diabetes. It is an active ingredient of Alogliptin Benzoate.

References

Zhang, Kun, et al. “A Developed HPLC Method for the Determination of Alogliptin Benzoate and Its Potential Impurities in Bulk Drug and Tablets.” Asian Journal of Pharmaceutical Sciences, vol. 10, no. 2, Apr. 2015, pp. 152–58, https://doi.org/10.1016/j.ajps.2015.01.001.

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url